Drug intelligence / Profile preview

BMS-986454

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Unspecified (route Not Yet Disclosed In Public Sources)[2]

Overview

BMS-986454 is an investigational small molecule drug developed by Bristol Myers Squibb for the treatment of autoimmune disorders. It is a new molecular entity currently in Phase I clinical trials, with its first-in-human studies focused on evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants. The precise mechanism of action has not been publicly disclosed as of June 2025. No orphan drug status has been granted to date[1][2][4][5].

Other names: BMS 986454BMS986454BMS-986454

Beyond the preview

Go deeper on BMS-986454.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986454.

Explore the full profile